Also trades as 2359.HK.

603259.SS

Premium GrowerAI neutral

WuXi AppTec Co., Ltd. · Healthcare · China · $65.8B cap · $941.8M/day traded

CNY 146.07 +1.1% · close 17 Nov · scored 18 Nov

Premium Grower: Strong business with the market behind it, priced at a premium.

Full research report (Aug 2026), free
96
Score
Get score and insider alerts
Quality
81
Value
45
Momentum
80

As of 18 Nov 2026, the MoatMap Score for WuXi AppTec Co., Ltd. (603259.SS) is 96/100, ranked against 25,000+ stocks in 38 markets (Quality 81, Value 45, Momentum 80, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
16.3x
peers 23.2x
ROE
30.0%
peers 3.1%
D/E
0.1x
peers 0.2x
Dividend %
1.4%
trailing yield
AI REVIEW

WuXi AppTec is a leading Chinese contract research, development and manufacturing organisation for drugmakers. It has strong scale, quality and cash generation. It asked S&P and Fitch to withdraw its ratings, and Moody's moved its outlook to negative. US restrictions on Chinese biotech suppliers remain a live risk, and new Chinese rules on cancer-drug development may raise costs for its domestic customers. The business is high quality, but the geopolitical overhang makes the outcome hard to underwrite.

ABOUT WUXI APPTEC CO., LTD.

Read

WuXi AppTec is a global provider of R&D and manufacturing services (CRDMO) enabling the pharmaceutical, biotech, and medical device industries. The company's competitive moat lies in its fully integrated, end-to-end platform that spans small molecule discovery, development, manufacturing, and cell/gene therapies. As a dominant global market leader, it benefits from high switching costs and a massive, diversified international client base.

FINANCIAL SUMMARY (CNY)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue22.9B39.4B40.3B39.2B45.5B18.7%56.0B61.7B75.6B29.0%
Net margin22.3%22.4%23.8%24.1%42.1%+19.8 pts————
EPS (CNY)1.83.03.33.36.739.9%8.912.4—85.6%
Share count—3.0B3.0B2.9B3.0B0.3%2.5B———
Balance sheet
Debt—5.9B5.7B5.0B8.4B12.8%8.5B———
Equity38.5B46.6B55.1B58.6B79.7B20.0%————
Debt/equity—0.1x0.1x0.1x0.1x0.0x————
Cash flow
Op. cash flow4.6B10.6B13.4B12.4B17.2B39.1%22.9B———
Cash flow margin20.0%27.0%33.2%31.6%37.8%+17.8 pts41.0%———
Investing CF-4.8B-9.7B-7.6B-5.5B-1.9B—————
Financing CF-1.7B-1.3B-3.9B-3.8B1.1B—————
PRICE (1Y) · CNY-12.7%
13514315115916730 Sep28 Oct17 Nov
SMA 50SMA 200

Price checkNo clear trendExperimental

No clear trend: not near its 52-week low, and not in a steady uptrend.

SwingsBumpy

Calmer than 51% of stocks we rank over the past year (volatility 42% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
CNY 146.07
RSI (14)
53.8
52-Week Range-15.6% from high
Low CNY 85.45High CNY 173.03

SCORE BREAKDOWN

Quality
81
ROIC
33.1%96.7
ROE
30.0%94.7
GP/Assets
29.7%64.5
Op. Margin
44.8%97.7
FCF/Assets
11.3%88.5
Piotroski
668.8
Int. Cover
50.0x89.5
D/E Ratio
0.09x63.8
Current Ratio
3.43x60.8
Value
45
P/E (TTM)
16.3x67.8
EV/EBITDA
13.0x53.8
P/FCF
37.7x32.5
P/B
4.4x28.2
P/S
7.9x27.9
Div Yield
1.4%44.9
Momentum
80
52W High %
84%77.2
RS 6M
62%94.7
SMA 50/200
1.26x93.5
EPS Rev 4W
+7.8%89.7
EPS Rev 12W
+9.3%82.2
EPS Improve
+14%32.2
Q Growth
132%87.6

FUNDAMENTALS

Market Cap
$65.8B
P/E (Forward)
14.4x
Gross Margin
54.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603259.SS are excluded.

TickerCompanyMkt CapScore
603259.SSWuXi AppTec Co., Ltd.(you)$65.8B96
ILMNIllumina, Inc.$40.7B76
IDXXIDEXX Laboratories, Inc.$44.1B74
AAgilent Technologies, Inc.$48.8B69
DGXQuest Diagnostics Incorporated$26.7B81
MEDPMedpace Holdings, Inc.$18.7B87
LONN.SWLonza Group AG$53.5B62
LHLabcorp Holdings Inc.$26.7B76
MTDMettler-Toledo International Inc.$33.5B71
IQVIQVIA Holdings Inc.$46.0B64

Peer medians: ROE 3.1% · P/E 23.2x · Gross margin 53.1%

Company Deep Dive

Read the full report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

View Deep Dive

WuXi AppTec Co., Ltd. (603259.SS): Stock Score Summary

WuXi AppTec Co., Ltd. (603259.SS) has a MoatMap Score of 96/100 based on Quality (81/100), Value (45/100), and Momentum (80/100) factor scores. WuXi AppTec is a leading Chinese contract research, development and manufacturing organisation for drugmakers. It has strong scale, quality and cash generation. It asked S&P and Fitch to withdraw its ratings, and Moody's moved its outlook to negative. US restrictions on Chinese biotech suppliers remain a live risk, and new Chinese rules on cancer-drug development may raise costs for its domestic customers. The business is high quality, but the geopolitical overhang makes the outcome hard to underwrite.

WuXi AppTec is a global provider of R&D and manufacturing services (CRDMO) enabling the pharmaceutical, biotech, and medical device industries. The company's competitive moat lies in its fully integrated, end-to-end platform that spans small molecule discovery, development, manufacturing, and cell/gene therapies. As a dominant global market leader, it benefits from high switching costs and a massive, diversified international client base.

Director dealings

From 10 Mar 2026 to 18 Nov 2026, MoatMap's records hold no purchases or sales of WuXi AppTec Co., Ltd. (603259.SS) shares by its directors.

603259.SS insider filings, last 180 days

Key Financial Metrics

PriceCNY 146.07
Market Cap$65.8B
P/E (TTM)16.35
P/E (Forward)14.38
Price/Book4.36
Return on Equity30.0%
Return on Invested Capital33.1%
Debt/Equity0.09x
Gross Margin54.5%
Operating Margin44.8%
Revenue Growth38.0%
Dividend Yield1.4%
Free Cash Flow$1.7B

WuXi AppTec Co., Ltd. operates in the Diagnostics & Research industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is WuXi AppTec Co., Ltd.’s (603259.SS) MoatMap Score?
The MoatMap Score for WuXi AppTec Co., Ltd. (603259.SS) is 96/100. It is a composite of Quality (81), Value (45), and Momentum (80), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does WuXi AppTec Co., Ltd. have an economic moat?
WuXi AppTec Co., Ltd. (603259.SS) has a Quality factor score of 81/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is WuXi AppTec Co., Ltd. in?
WuXi AppTec Co., Ltd. (603259.SS) operates in the Healthcare sector, specifically the Diagnostics & Research industry (China).